← Back to Search

Bicaval cannulation for Atrial Fibrillation

N/A
Waitlist Available
Led By Jean-François Morin, MD,FRCSC
Research Sponsored by Dr. Jean-Francois Morin
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up during hospital admission and clinic visit at 30 days from hospital discharge date.
Awards & highlights

Study Summary

This trial is a pilot RCT to study the efficacy of 2 types of venous cannulation during surgery for CABG in reducing the incidence of AF. 40 patients will be included, with 20 in each group. The primary endpoint is any episode of AF lasting >5 minutes or any episode leading to hemodynamic compromise or symptoms. Patients will be followed up at 1 month.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during hospital admission and clinic visit at 30 days from hospital discharge date.
This trial's timeline: 3 weeks for screening, Varies for treatment, and during hospital admission and clinic visit at 30 days from hospital discharge date. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Atrial fibrillation
Secondary outcome measures
Increase in Left atrial index
Right ventricular dysfunction
Tricuspid regurgitation

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Bicaval cannulationExperimental Treatment1 Intervention
Cannulating the superior and inferior vena cavae with separate cannulas, inserted through 2 separate incisions in the right artium going into the superior and inferior vena cavae. No slush added. This technique is used in Right heart procedure (Pulmonic and tricuspid valve) and mitral valve procedures. This technique is not routinely used in CABG operations.
Group II: Cavoatrial cannulationActive Control1 Intervention
Cannulation of the atrium with 2-stage venous cannula.

Find a Location

Who is running the clinical trial?

Dr. Jean-Francois MorinLead Sponsor
Jean-François Morin, MD,FRCSCPrincipal InvestigatorJewish General Hospital

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could I potentially take part in this research project?

"Atrial fibrillation is a prerequisite for anyone looking to participate in this experiment. Furthermore, all volunteers must be between 18-100 years old. In total, the researchers are hoping around 40 people will enroll."

Answered by AI

Are the participants in this clinical trial restricted to those over 18 years old?

"In order to be eligible for this trial, applicants must between 18 and 100 years old. There are 12 trials specifically designed for patients under the age of 18 and 498 for elderly individuals."

Answered by AI

How many people are being given the chance to participate in this experiment?

"That is accurate, the web portal clinicaltrials.gov has information indicating that this study is actively searching for willing participants. The trial was first posted on July 1st, 2022 and last updated on August 17th, 20212. In total, the research requires 40 individuals from a single site."

Answered by AI

Can new patients still join the trial?

"The research team is currently looking for patients that match the eligibility criteria. The study was originally posted on July 1st, 2020 and the most recent update was on August 17th, 2020."

Answered by AI
Recent research and studies
Heart and VesselsJournal
Impact of Volume Status on the Incidence of Atrial Fibrillation Following Aortic Arch Repair
Matsuura, Kaoru, Hitoshi Ogino, Hitoshi Matsuda, Kenji Minatoya, Hiroaki Sasaki, Toshikatsu Yagihara, and Soichiro Kitamura. 2007. “Impact of Volume Status on the Incidence of Atrial Fibrillation Following Aortic Arch Repair”. Heart and Vessels. Springer Science and Business Media LLC. doi:10.1007/s00380-006-0928-y.
Physiological ReviewsJournal
Pathophysiological Mechanisms of Atrial Fibrillation: A Translational Appraisal
Schotten, Ulrich, Sander Verheule, Paulus Kirchhof, and Andreas Goette. 2011. “Pathophysiological Mechanisms of Atrial Fibrillation: A Translational Appraisal”. Physiological Reviews. American Physiological Society. doi:10.1152/physrev.00031.2009.
Journal of Critical CareJournal
Magnesium Status and Magnesium Therapy in Cardiac Surgery: A Systematic Review and Meta-analysis Focusing on Arrhythmia Prevention
Fairley, Jessica L., Ling Zhang, Neil J. Glassford, and Rinaldo Bellomo. 2017. “Magnesium Status and Magnesium Therapy in Cardiac Surgery: A Systematic Review and Meta-analysis Focusing on Arrhythmia Prevention”. Journal of Critical Care. Elsevier BV. doi:10.1016/j.jcrc.2017.05.038.
The Annals of Thoracic SurgeryJournal
Prophylactic Magnesium Does Not Prevent Atrial Fibrillation After Cardiac Surgery: A Meta-analysis
Cook, Richard C., Michael H. Yamashita, Mark Kearns, Krishnan Ramanathan, Ken Gin, and Karin H. Humphries. 2013. “Prophylactic Magnesium Does Not Prevent Atrial Fibrillation After Cardiac Surgery: A Meta-analysis”. The Annals of Thoracic Surgery. Elsevier BV. doi:10.1016/j.athoracsur.2012.09.008.
~15 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top